Pfizer Inc. aims to expand its vaccination business by becoming a leader in the new gene-based technology behind its successful Covid-19 photographs.
Pfizer will develop new photographs using technology called mRNA to target other viruses and pathogens beyond the coronavirus, CEO Albert Bourla said in an interview. He said the company’s scientists and engineers have gained a decade of experience over the past year working on the Covid-19 vaccine with BioNTech SE in Germany and are ready to track mRNA alone.
“There is a technology that has proven dramatic and potentially dramatic impact,” Mr Bourla said. “We are the best positioned company right now to take the next step because of our size and expertise.”
Pfizer will increase research and technology development, including the addition of at least 50 employees whose tasks will include mRNA and will leverage the new mRNA manufacturing network it has assembled over the past year to compete.
“We are now ahead and we intend to keep the gap,” he said of the mRNA vaccine market.